Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT05775939
Official study title

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Study summary

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedFludeoxyglucose F-18 and Positron Emission Tomography

Plus 2 other study approaches.

Who it may be forLung Carcinoma · Esophageal Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 10, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Thomas Jefferson University

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Thomas Jefferson University
Interventions being studied
Other: Fludeoxyglucose F-18; Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Other: Questionnaire Administration
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Provide signed and dated informed consent form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Male or female, aged \>= 18
  • Life expectancy \>= 3 months as assessed by Radiation Oncologist
  • Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose)
  • Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer
  • Planned radiation treatment course for management of lung or esophageal cancer \
  • Both standard and hypofractionation schedules are permitted
Reasons someone may not be able to joinExclusion criteria
  • Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
  • Palliative radiation doses defined as 20 Gy in 5 fractions

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Thomas Jefferson University HospitalPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 10, 2026. Always confirm current availability with the study team.

View original record ↗